Features - Teva Pharmaceutical Industries

Filter

Popular Filters

1 to 25 of 219 results

Teva and Dr Reddy’s latest to launch generic Lunesta in USA

16-04-2014

Two more companies have debuted generic versions of the insomnia drug Lunesta (eszopiclone) tablets,…

Dainippon Sumitomo PharmaDr Reddy's LaboratoriesGenericsLunestaMarkets & MarketingNeurologicalNorth AmericaSunovion PharmaceuticalsTeva Pharmaceutical IndustriesUSA

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

11-04-2014

The full year report from Anglo-Swedish drug major AstraZeneca (LSE: AZN) in February was full of optimism.…

AstraZenecaInterviewsIressaOncologyPharmaceuticalUK

Teva launches first generic Lovaza in USA

Teva launches first generic Lovaza in USA

08-04-2014

Israel-based Teva Pharmaceutical Industries says it has received US Food and Drug Administration approval…

Cardio-vascularGenericsGlaxoSmithKlineLovazaMarkets & MarketingRegulationTeva Pharmaceutical IndustriesUSA

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

07-04-2014

Uptake of biosimilars in Europe has increased as a result of member states’ policies, according to…

BiosimilarsEuropeFilgrastimInterviewsMarkets & MarketingRegulationSandoz

EGA Biosimilars: European monitoring and global business opportunities

EGA Biosimilars: European monitoring and global business opportunities

07-04-2014

The spotlight was on the European uptake of biosimilars at the European Generic medicines Association’s…

BiosimilarsEuropeGlobalInterviewsMarkets & Marketing

Actavis forks out $100 million for Thai generics firm

Actavis forks out $100 million for Thai generics firm

02-04-2014

Ireland-headquartered US generic major Actavis has acquired Silom Medical Company, a privately held generic…

Asia-PacificAurobindo PharmaGenericsMergers & AcquisitionsSilom Medical CompanyTeva Pharmaceutical Industries

Executive Q&A: Epigenomics’ chief executive Dr Thomas Taapken

Executive Q&A: Epigenomics’ chief executive Dr Thomas Taapken

01-04-2014

The Pharma Letter interviewed chief executive Dr Thomas Taapken about Epigenomics’ lead product, increasing…

BiotechnologyEpi proColonEpigenomicsGermanyInterviewsOncology

Lilly's Alimta patent upheld through 2022

Lilly's Alimta patent upheld through 2022

01-04-2014

US pharma major Eli Lilly says that the US District Court for the Southern District of Indiana has ruled…

AlimtaEli LillyLegalNorth AmericaOncologyPatentsPharmaceuticalTeva Pharmaceutical IndustriesUSA

US Supreme Court agrees to hear Teva’s Copaxone patent appeal

US Supreme Court agrees to hear Teva’s Copaxone patent appeal

01-04-2014

Israel’s Teva Pharmaceutical Industries, the world largest generic drugmaker, says that the US Supreme…

CopaxoneLegalNeurologicalNorth AmericaPatentsPharmaceuticalTeva Pharmaceutical IndustriesUSA

US District Court upholds Mylan's US patents on Perforomist Inhalation Solution

25-03-2014

US generics major Mylan says the US District Court for the Northern District of West Virginia issued…

GenericsLegalMylan LaboratoriesNorth AmericaPatentsPerforomistRespiratory and PulmonaryTeva Pharmaceutical IndustriesUSA

Interview: Arnaud Grunwald of Model N on taking a holistic approach to revenue management

Interview: Arnaud Grunwald of Model N on taking a holistic approach to revenue management

20-03-2014

As health care budgets are squeezed worldwide and access issues continue to make the headlines, the price…

GlobalInterviewsPharmaceuticalPricing

Executive Q&A: ADC Therapeutics’ chief executive Michael Forer

Executive Q&A: ADC Therapeutics’ chief executive Michael Forer

19-03-2014

In an interview with The Pharma Letter, CEO Michael Forer discusses ADC Therapeutics' developing pipeline…

ADC TherapeuticsBiotechnologyInterviewsNorthern EuropeOncology

Executive Q&A: Fibrotech's chief executive Darren Kelly

Executive Q&A: Fibrotech's chief executive Darren Kelly

18-03-2014

The Pharma Letter interviewed chief executive Darren Kelly about Fibrotech’s ethos and its lead product,…

AustraliaBiotechnologyFibrotechInterviewsNephrology and Hepatology

Pharma Summit: Sanofi president Elias Zerhouni calls for harmony and evolution in pharma

Pharma Summit: Sanofi president Elias Zerhouni calls for harmony and evolution in pharma

14-03-2014

Health care is a human right and the pharma industry must evolve to meet future challenges, claims Elias…

EuropeHealthcareInterviewsPharmaceuticalSanofi

Pharma Summit: Rethinking the future – new business models for pharma

Pharma Summit: Rethinking the future – new business models for pharma

14-03-2014

The way pharma works needs to change with an increasing focus on collaborations, sharing data and access…

HealthcareInterviewsLundbeckPfizerPharmaceuticalPricingUK

Modest growth forecast for global migraine market to 2023

Modest growth forecast for global migraine market to 2023

13-03-2014

The global migraine treatment market value is expected to undergo a modest increase over the coming years,…

CoLucid PharmaceuticalsGloballamiditanMarkets & MarketingMerck & CoMK-1602NeurologicalNuPathePharmaceuticalTeva Pharmaceutical IndustriesZecuity

Teva agrees $27.6 million settlement with US Justice Dept

Teva agrees $27.6 million settlement with US Justice Dept

12-03-2014

US subsidiaries of Israeli generics giant Teva Pharmaceutical Industries have agreed to pay the US government…

ClozapineFinancialGenericsIvaxLegalNeurologicalNorth AmericaTeva Pharmaceutical IndustriesUSA

Teva gains approval for generic Evista in the USA

Teva gains approval for generic Evista in the USA

04-03-2014

Israel-based Teva Pharmaceutical Industries says it has received approval from the US Food and Drug Administration…

Anti-Arthritics/RheumaticsEli LillyEvistaGenericsNorth AmericaRegulationTeva Pharmaceutical IndustriesUSA

Alexza’s partner Teva launches antipsychotic Adasuve in USA

Alexza’s partner Teva launches antipsychotic Adasuve in USA

04-03-2014

US drug developer Alexza Pharmaceuticals says that its marketing partner, Israel-based generic drugs…

AdasuveAlexza PharmaceuticalMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalTeva Pharmaceutical IndustriesUSA

Natco prevails in Indian Copaxone patent dispute with Teva

Natco prevails in Indian Copaxone patent dispute with Teva

03-03-2014

Hyderabad, India-based Natco Pharma has won a significant patent battle against Israeli generics giant…

Asia-PacificCopaxoneGenericsIndiaNatco PharmaPatents & Trade marksTeva Pharmaceutical Industries

Israel's Clal Biotech in talks to sell Andromeda unit

28-02-2014

In an announcement to the Stock Exchange, Israeli firm Clal Biotechnology Industries said that, on February…

Andromeda BiotechBiotechnologyClal BiotechnologyDiabetesDiaPep277Mergers & AcquisitionsTeva Pharmaceutical Industries

Teva UK launches Lonquex, a new long-acting G-CSF competitor to Amgen drugs

Teva UK launches Lonquex, a new long-acting G-CSF competitor to Amgen drugs

26-02-2014

The local subsidiary of Israeli generics giant Teva Pharmaceutical Industries has launched Lonquex (lipegfilgrastim)…

AmgenBiosimilarsGenericsLonquexMarkets & MarketingNorthern EuropeOncologyTeva Pharmaceutical IndustriesUK

1 to 25 of 219 results

Back to top